MedTrace Logo

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

NCT03732638 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1590

Last updated 2024-06-07

Study results available
· View outcomes & findings →

Summary

The purpose of this is study is to compare the efficacy of BHV-3000 (rimegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.

Conditions

Interventions

DRUG

Rimegepant

Rimegepant 75 mg tablet EOD

DRUG

Placebo

Placebo tablet to match rimegepant tablet EOD

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-14
Primary Completion
2019-12-10
Completion
2021-02-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03732638 on ClinicalTrials.gov